- South Korea
- /
- Personal Products
- /
- KOSDAQ:A353190
Hurum Third Quarter 2024 Earnings: EPS: ₩19.00 (vs ₩26.00 in 3Q 2023)
Hurum (KOSDAQ:353190) Third Quarter 2024 Results
Key Financial Results
- Revenue: ₩27.5b (up 5.0% from 3Q 2023).
- Net income: ₩734.7m (down 27% from 3Q 2023).
- Profit margin: 2.7% (down from 3.8% in 3Q 2023). The decrease in margin was driven by higher expenses.
- EPS: ₩19.00 (down from ₩26.00 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hurum Earnings Insights
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Personal Products industry in South Korea.
Performance of the South Korean Personal Products industry.
The company's shares are down 5.1% from a week ago.
Risk Analysis
You should learn about the 2 warning signs we've spotted with Hurum (including 1 which is potentially serious).
Valuation is complex, but we're here to simplify it.
Discover if Hurum might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A353190
Hurum
Researches, develops, manufactures, and distributes health supplements in South Korea and internationally.
Acceptable track record with mediocre balance sheet.